Green M, Reyes J, Nour B, Kaufmann M, Geraci L, Beatty D, Wilson J, Todo S, Tzakis A; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1994 Oct 4-7; 5.
Univ of Pittsburgh Sch of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, PA.
Prophylaxis with HD-ACY alone did not result in a decreased rate of CMV disease after PLTx at our institution. In order to determine the role of HD-ACY in the prevention of CMV and EBV disease in patients prophylaxed with GAN for the first 2 post-operative weeks, patients undergoing first-time PLTx were stratified according to donor (D) and recipient (R) serologic status against CMV and randomized to receive either HD-ACY (800 mg/m2 PO QID for 1st year post-LTx) or no HD-ACY. Between 7/92 & 3/94, 48/57 eligible patients were enrolled in the study. D/R CMV serologies in these children were: D+/R- 13, D-/R+ 11, D+/R+ 7, D-/R- 17. 45/48 are alive 1 to 20 months after PLTx. CMV disease was diagnosed in 6/24 pts on HD-ACY compared with 2/24 controls (p=N.S.). For D+/R- recipients, CMV disease was seen in 4/7 HD-ACY pts compared to 0/6 controls (p=0.07). Rates of EBV disease were 6/24 vs. 5/24 (HD-ACY vs. control). We conclude that HD-ACY does not decrease CMV or EBV disease after PLTx. The trend towards an increased rate of CMV among children treated with HD-ACY was an unexpected & intriguing finding.
Publication Types:
Keywords:
- Acyclovir
- Child
- Clinical Trials as Topic
- Cytomegalovirus
- Cytomegalovirus Infections
- Ganciclovir
- Herpesvirus 4, Human
- Humans
- Immunization, Passive
- Kidney Transplantation
- Liver Transplantation
- Pancreas Transplantation
- Tissue Donors
- surgery
- therapy
- transplantation
Other ID:
UI: 102213631
From Meeting Abstracts